U.S. Water Utilities Stock News

Event context and recent stock performance Marcus & Millichap (MMI) has been drawing investor attention after recent share price moves, with the stock up about 0.8% over the past day and 2.5% over the past week. Those gains contrast with a small decline over the past month and a roughly 6.9% decline over the past 3 months, raising questions about how short term momentum lines up with the company’s underlying fundamentals. See our latest analysis for Marcus & Millichap. Stepping back, the...

On January 22, 2026, First Industrial Realty Trust refinanced and amended its major unsecured term loans, extending maturities into 2029 and 2030, expanding capacity on one facility to US$375 million, and removing a 10 basis point SOFR adjustment while keeping the loans interest-only. The revised agreements also introduce potential sustainability-linked pricing and tighten covenant structures, reshaping the REIT’s funding profile and flexibility for future capital allocation decisions. Next,...

If you are wondering whether Ralliant's current share price gives you good value for your money, you are not alone. This article is built to help you assess that. Over the short term, the stock has seen a 1.4% decline over the past week, a 4.0% gain over the last 30 days and a 3.4% return year to date, which has likely caught the attention of investors tracking short term moves. Recent coverage has focused on Ralliant's position in the tech sector and how investors are reacting to its latest...

Church & Dwight (CHD) just posted its FY 2025 third quarter numbers, with revenue of US$1,585.6 million and basic EPS of US$0.75, alongside net income of US$182.2 million. The company has seen quarterly revenue move from US$1,511.2 million in Q2 2024 to US$1,582.0 million in Q4 2024 and then to US$1,585.6 million in Q3 2025. Over the same periods, basic EPS shifted from US$1.00 to US$0.77 and then to US$0.75, creating a picture in which the headline growth story is now as much about how...

On 29 January 2026, Fractyl Health reported positive six-month randomized midpoint data from its REMAIN-1 study, showing Revita-treated patients had less weight regain and better cardiometabolic markers than sham after stopping GLP-1 drugs, and outlined plans to seek FDA De Novo classification. An interesting angle is that Revita is being explored specifically as a tool to help maintain weight loss after GLP-1 discontinuation, targeting a growing clinical gap. Against this backdrop, we’ll...

In January 2026, Curant Health's Curant Rare announced a collaboration with Cencora to offer an integrated commercialization solution for rare disease therapies, combining Cencora’s logistics, pharmacovigilance and market access support with Curant Rare’s specialty pharmacy and patient engagement services. A distinctive aspect of this partnership is its focus on real-world evidence and patient-reported outcomes, aiming to improve both market access and the overall patient experience in rare...

In recent weeks, Camtek has attracted heightened attention as analysts anticipate year-over-year gains in earnings and revenue ahead of its upcoming results, while the stock has outperformed both its sector and the broader market over the past month. What stands out is that, even with a current Zacks Rank of Hold and some valuation concerns, analyst estimate revisions and an overall “Outperform” consensus suggest growing confidence in the company’s business health and profitability. With...

If you are wondering whether Alcoa's current share price still offers value after a strong run, this article will walk you through what the numbers are saying about the stock. The shares closed at US$56.81, with returns of 6.9% over the last 30 days, a 62.9% gain over the past year and 183.9% over five years, although the latest 7 day move was an 8.7% decline and year to date returns sit at 0.5%. Recent coverage of Alcoa has focused on how its share price reacts to shifts in sentiment around...

For investors wondering whether MKS is still reasonably priced after its recent gains or if expectations are getting ahead of reality, this article focuses squarely on what the current share price might be implying. Over the past year, MKS has recorded a 109.6% return, with 47.3% over the last month and 8.5% in the past week. These moves put valuation firmly in the spotlight for anyone considering the recent momentum. Recent coverage has highlighted MKS in the context of semiconductor sector...

If you are wondering whether Cavco Industries at around US$492 per share still offers good value after a strong multi year run, this article will walk through what the current price could mean. The stock has seen a 26.3% decline over the last 7 days and a 16.8% decline year to date, while the 3 year and 5 year returns stand at 79.6% and 138.5% respectively. Recent coverage has highlighted Cavco Industries as a long term compounder in manufactured housing and as part of broader discussions on...

OceanFirst Financial (NasdaqGS:OCFC) reported its latest quarterly results with growth in commercial loans and deposits. Profitability was affected by higher expenses tied to outsourcing and merger related activity. The company also recorded net loan charge offs during the quarter. For you as an investor following regional banks, OceanFirst Financial sits in the middle of several important trends, including competition for deposits and a focus on commercial lending. The latest update around...

Financial Institutions (FISI) closed out FY 2025 with fourth quarter revenue of US$60.7 million and basic EPS of US$0.98, while trailing twelve month revenue came in at US$233.3 million and EPS at US$3.65. The company has seen quarterly revenue move from US$47.0 million in Q3 2024 to US$60.7 million in Q4 2025, with quarterly EPS shifting from a loss of US$5.07 in Q4 2024 to a profit of US$0.98 in Q4 2025. This sets the stage for investors to focus on how sustainable these margin and earnings...

Invesco Mortgage Capital (IVR) just posted its FY 2025 numbers with Q4 revenue of US$56.1 million and basic EPS of US$0.68, giving investors a fresh read on how the portfolio is trading through the mortgage market. Over recent periods, revenue has ranged from US$8.5 million in Q4 2024 to US$57.9 million in Q3 2025, while quarterly EPS has swung between a loss of US$0.40 in Q2 2025 and a gain of US$0.74 in Q3 2025, setting the backdrop for today’s print. With a trailing 12 month net margin of...

Moog (MOG.A) has opened Q1 2026 earnings season with a fresh set of numbers, coming off a recent quarter where revenue was US$1.0 billion and basic EPS came in at US$2.10, backed by trailing twelve month EPS of US$7.42 on revenue of US$3.9 billion. The company has seen revenue move from US$917.1 million in Q4 2024 to US$1.0 billion in Q4 2025, while quarterly basic EPS stepped up from US$1.39 to US$2.10 over the same stretch, setting the stage for investors to weigh how sustainable that...

United States Antimony (UAMY) is in focus after funding a new commercial scale hydrometallurgical processing facility in Bolivia, paired with exclusive rights to replicate the process in North America and Australia. See our latest analysis for United States Antimony. The funding news lands after a volatile stretch, with a 32.44% 7 day share price decline and an 11.58% 1 day drop, even though the 30 day share price return is 46.02% and the 1 year total shareholder return is very large. This...

Wintrust Financial (WTFC) has drawn fresh attention after reporting higher fourth quarter net interest income and net income year over year, along with a 10% increase to its quarterly common dividend and a separate preferred stock dividend declaration. See our latest analysis for Wintrust Financial. Those stronger fourth quarter earnings and higher dividends come after a steady run in the share price, with a 30 day share price return of 5.47% and a 90 day share price return of 13.42%, while...

Dow Inc. recently reported fourth-quarter 2025 results showing sales of US$9,460 million and a net loss of US$1,543 million, alongside full-year sales of US$39,968 million and a net loss of US$2,623 million. At the same time, the company launched its Transform to Outperform program, including about 4,500 job cuts and heavier use of artificial intelligence and automation to reset its cost base and operations. Next, we’ll examine how Dow’s large-scale Transform to Outperform cost program...

BMO Capital’s downgrade of First Solar (FSLR), driven by concern over Tesla’s vertically integrated solar ambitions and potential pressure on module pricing, has sharpened investor focus on the company’s competitive position and valuation. See our latest analysis for First Solar. The recent analyst downgrades and concern over Tesla’s plans have coincided with a 30 day share price return of 13.67% decline and a year to date share price return of 17.80% decline. However, the 1 year total...

If you are wondering whether Fabrinet's share price reflects its underlying worth, this article walks through the key numbers and what they might mean for you. Fabrinet's stock recently closed at US$489.44, with returns of 4.8% over 7 days, 7.5% over 30 days, 2.1% year to date, 126.4% over the past year, 267.8% over 3 years and 448.3% over 5 years, providing useful context for any valuation work. Recent coverage around Fabrinet has focused on its role as a tech manufacturing partner. This...

First Reliance Bancshares (FSRL) has put up a busy FY 2025 so far, with Q3 revenue at US$12.1 million, basic EPS of US$0.34 and net income of US$2.7 million setting the tone for its latest update. The company has seen revenue move from US$10.2 million in Q2 2024 to US$13.8 million in Q2 2025, with EPS shifting from US$0.25 to US$0.46 over the same period. This gives you a clearer picture of how the income statement has evolved ahead of the current quarter. With net profit margins over the...

Central Pacific Financial (CPF) capped FY 2025 with fourth quarter total revenue of US$73.9 million and basic EPS of US$0.86, while trailing twelve month revenue came in at US$277.0 million and EPS at US$2.88. Over the last few quarters, the company has seen revenue move from US$57.6 million in Q4 FY 2024 to US$73.9 million in Q4 FY 2025, with quarterly EPS shifting from US$0.42 to US$0.86 over the same period. With trailing net margin now at 28.0% and profit growth flagged as strong in the...

Dover (DOV) closed out FY 2025 with fourth quarter revenue of US$2,099 million and basic EPS of US$2.02, alongside net income excluding extra items of US$274.8 million. The company has seen quarterly revenue move from US$1,930 million and EPS of US$1.74 in Q4 2024 to US$2,099 million and EPS of US$2.02 in Q4 2025, while trailing 12 month net profit margins have softened from 18.1% to 13.6%. This sets up a results season in which investors are likely to focus squarely on how sustainable those...

In January 2026, Precigen, Inc. reported that an independent expert consensus paper in The Laryngoscope recommended its FDA-approved HPV-specific immunotherapy PAPZIMEOS (zopapogene imadenovec) as the new first-line standard of care for adults with recurrent respiratory papillomatosis, shifting focus from repeated surgery to treating the underlying infection. Because the paper was sponsored by the Recurrent Respiratory Papillomatosis Foundation and shaped with input from patients and...

If you are wondering whether UnitedHealth Group's current share price still reflects its long term potential, you are not alone. This article is designed to help you make sense of the valuation story. The stock has recently faced sharp moves, with a 19.5% decline over the past week and a 45.8% decline over the last year, adding fresh questions about both risk and opportunity at the current price of US$286.93. These moves sit against a backdrop of ongoing attention on large US healthcare...